Welcome to our dedicated page for Maravai Lifesciences Holdings news (Ticker: MRVI), a resource for investors and traders seeking the latest updates and insights on Maravai Lifesciences Holdings stock.
Maravai LifeSciences Holdings, Inc. reports recurring developments as a life sciences supplier of reagents and services for drug therapy, diagnostics, vaccine and human disease research. Company updates center on its TriLink nucleic acid synthesis business, including mRNA, oligonucleotides and CleanCap-related technologies, and its Cygnus biologics safety testing business, including host cell protein ELISA kits, impurity detection assays, reagents and services.
News about MRVI commonly covers quarterly financial results, segment revenue trends, guidance, restructuring and operating cost initiatives, investor conference participation, executive and board changes, and product or commercial updates tied to researchers, biotech innovators, vaccine developers, diagnostics companies and cell and gene therapy customers.
Maravai LifeSciences (NASDAQ: MRVI) will participate in the Jefferies Global Healthcare Conference in New York City on June 4, 2026, at 12:50 p.m. Eastern Time. CFO Raj Asarpota will join a fireside chat, with a live and archived webcast available on the company’s investor relations website.
Maravai LifeSciences (NASDAQ: MRVI) reported Q1 2026 results: revenue $65.8M (+40.5% YoY), net loss $(6.4)M, and Adjusted EBITDA $20.3M. TriLink revenue was $47.5M (+65.1%) including $14.3M of CleanCap COVID orders; TriLink base (ex-COVID) grew 15.4% YoY. Free cash flow returned to positive at $4.2M. Management raised full‑year 2026 guidance to $205–215M revenue and $30–32M Adjusted EBITDA.
Maravai LifeSciences (NASDAQ: MRVI) will report Q1 2026 financial and operating results after market close on Thursday, May 7, 2026 and will host a conference call and webcast the same day at 2:00 p.m. PT / 5:00 p.m. ET.
Investors can join by telephone (dial-in numbers provided) or via live and archived webcast on the company's Investors website.
Maravai LifeSciences (NASDAQ: MRVI) reported Q4 2025 revenue of $49.9M, net loss of $(63.0)M, and Adjusted EBITDA (non-GAAP) of $0.5M. For full year 2025, revenue was $185.7M, net loss $(230.8)M, and Adjusted EBITDA (non-GAAP) $(31.2)M.
The company issued 2026 guidance of $200M–$210M revenue and $18M–$20M Adjusted EBITDA. Management cited a lack of high-volume CleanCap orders as the primary driver of TriLink declines and noted operational restructuring and cost reductions underway.
Maravai LifeSciences (NASDAQ: MRVI) will announce fourth quarter and full year 2025 financial and operating results after market close on Wednesday, February 25, 2026. The company will host a conference call and webcast the same day at 2:00 p.m. PT / 5:00 p.m. ET.
Dial-in numbers are 1-800-343-4136 or 1-203-518-9843 with Conference ID: MARAVAI. A live and archived webcast will be available in the Investors section at https://investors.maravai.com.
Maravai LifeSciences (NASDAQ: MRVI) will participate in investor conferences in November 2025 with CFO Raj Asarpota presenting via fireside chats. Dates/times: November 12, 2025 at 10:00 a.m. EST at the Stifel Healthcare Conference in New York, and November 19, 2025 at 10:00 a.m. GMT at the Jefferies Healthcare Conference in London.
A live webcast of each presentation will be available on the company’s Investor Relations website under News & Events, IR Calendar, and archived recordings will be posted after each event.
Maravai LifeSciences (NASDAQ: MRVI) reported third quarter 2025 results for the period ended September 30, 2025: revenue $41.6M, net loss $(45.1)M, and Adjusted EBITDA $(10.8)M. Nucleic Acid Production revenue was $25.4M (down 52.9% YoY) driven by a lack of high-volume CleanCap commercial vaccine orders, while Biologics Safety Testing revenue was $16.3M (up 7.2% YoY).
The company reiterated full-year 2025 revenue guidance of approximately $185.0M and said TriLink is expected to deliver double-digit sequential revenue growth in Q4 2025; management noted restructuring and cost-reduction initiatives are on track.
Maravai LifeSciences (NASDAQ: MRVI) will announce third quarter 2025 financial and operating results after market close on Thursday, November 6, 2025. The company will host an earnings conference call and webcast the same day at 2:00 p.m. PT / 5:00 p.m. ET.
Investors may join by phone at (800) 579-2543 or (785) 424-1789 using Conference ID: MARAVAI, or listen via live or archived webcast at https://investors.maravai.com.
Maravai LifeSciences (NASDAQ: MRVI) reported challenging Q2 2025 financial results with revenue declining 31.7% year-over-year to $47.4 million. The company posted a net loss of $(69.8) million, including a $30.4 million goodwill impairment, and negative Adjusted EBITDA of $(10.4) million.
Under new leadership with CEO Bernd Brust and CFO Raj Asarpota, Maravai announced a major restructuring targeting over $50 million in annualized cost savings through labor, facilities, and productivity initiatives. The base business excluding high-volume CleanCap grew 5%, driven by Cygnus products and Biologics Safety Testing segment growth of 9.9%.
The company has withdrawn its 2025 guidance as the new management team conducts a comprehensive business review, with expectations for Net Loss Reduction, Positive Adjusted EBITDA and Free Cash Flow by second half 2026.
Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services, has scheduled its second quarter 2025 financial results announcement for Monday, August 11, 2025, after market close.
The company will host a conference call and webcast at 2:00 p.m. PT/ 5:00 p.m. ET on the same day. Investors can join via phone by dialing (800) 267-6316 or (203) 518-9783 with Conference ID MARAVAI, or access the webcast through the "Investors" section of Maravai's website.